Year-end Sale % OFF 
Abstract
To the Editor: The incidence and severity of COVID-19 among patients with autoimmune bullous skin diseases (AIBD) have not been characterized in large populations.1-3 We assessed the severity and mortality of COVID-19 in patients with AIBD, with a special interest in a potential risk factor related to previous treatment with rituximab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
